The company is devoted to developing innovative optogenetic therapies for chronic pain management, with the ultimate aim of revolutionizing the field of pain relief. Our therapies are in development ...

A KAIST research team led by Professor Won Do Heo (Department of Biological Sciences) has developed an optogenetic platform, RELISR (REversible LIght-induced Store and Release), that enables precise ...

BOSTON, Nov. 12, 2025 /PRNewswire/ -- Modulight Biotherapeutics, developer of novel optogenetic platform for the treatment of neurological disorders, announced today the closing of its Seed funding ...

A novel optogenetic screening platform enables control over previously intractable biological systems. Using the screening platform, scientists have been able to selectively activate the integrated ...